Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Climb Bio (CLYM) Income from Continuing Operations (2020 - 2026)

Climb Bio filings provide 7 years of Income from Continuing Operations readings, the most recent being 13697000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations rose 33.93% to 13697000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 52526000.0 through Mar 2026, up 43.49% year-over-year, with the annual reading at 59560000.0 for FY2025, 19.39% up from the prior year.
  • Income from Continuing Operations hit 13697000.0 in Q1 2026 for Climb Bio, up from 17470000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1664000.0 in Q1 2024 and bottomed at 54887000.0 in Q2 2024.
  • Average Income from Continuing Operations over 5 years is 13332058.82, with a median of 8947000.0 recorded in 2024.
  • The largest annual shift saw Income from Continuing Operations skyrocketed 92.62% in 2024 before it crashed 1145.85% in 2025.
  • Climb Bio's Income from Continuing Operations stood at 8794000.0 in 2022, then skyrocketed by 57.1% to 3773000.0 in 2023, then tumbled by 122.37% to 8390000.0 in 2024, then crashed by 108.22% to 17470000.0 in 2025, then rose by 21.6% to 13697000.0 in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Income from Continuing Operations are 13697000.0 (Q1 2026), 17470000.0 (Q4 2025), and 12855000.0 (Q3 2025).